Last year, Pfizer reported PF-07304814, a different small molecule inhibitor of SARS-CoV-2’s main protease. The work to develop that compound began during the 2002-2003 outbreak of SARS-CoV ...

Pfizer has published a paper demonstrating that its candidate drug PAXLOVID is safe and has antiviral effects on SARS-CoV-2. All data and statistics are based on publicly available data at the ...

Neutralizing antibody responses to SARS-CoV-2 in seropositive and naïve individuals before and after CoronaVac or BNT162b2 vaccination. (Panels A to D) The half maximum inhibitory concentration ...

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ... Texas Medical Branch and Pfizer studied the Pfizer ...

In-vitro studies conducted to date show that the clinical candidate PF-07321332 is a potent protease inhibitor with potent anti-viral activity against SARS-CoV-2 This is the first orally ...

Washington, D.C. - June 9, 2021 - The Pfizer COVID-19 vaccine is protective against several SARS-CoV-2 variants that have emerged, according to new research presented in the journal mBio ...

What The Study Did: This study describes an association between the Pfizer-BioNTech BNT162b2 vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom was the first to authorize emergency use of the Pfizer–BioNTech mRNA vaccine. On December 8, 2020, within 24 ...

The formulated vaccine demonstrated comparable responses against SARS-CoV-2 versus the companies ... In a separate Phase 2 trial, Pfizer evaluated trivalent (tIRV) influenza mRNA standalone ...

Federally funded Johns Hopkins team finds the virus ‘reprograms’ neutrophils to impair production of immune cells critical ...